Metastatic Lung Adenocarcinoma to the Uterus Mimicking a Primary Uterine Malignancy: A Case Report
Cancer Reports · 2026
DOI: 10.1002/cnr2.70706 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cancer Reports, 2026. Verfasst von Pengpeng Sun und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Yancheng TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Yancheng, Jiangsu, People's Republic o…. Hauptthemen laut MEDLINE: Lung Neoplasms, Uterine Neoplasms, Adenocarcinoma of Lung. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jiangsu Vocational College of Medicine University-Local Collaborative Innovation Research Project.
Abstract (Originalsprache)
Background
Lung adenocarcinoma is the most prevalent subtype of non‐small cell lung cancer and exhibits a high tendency for distant metastasis. However, uterine metastasis with synchronous multiorgan involvement is extremely rare and prone to misdiagnosis due to atypical clinical presentations. To date, fewer than 20 cases of lung adenocarcinoma metastasizing to the uterus have been documented globally, most of which present with typical gynecological symptoms, making our atypical case highly educational and complementary to existing clinical data. Case Herein, we describe a 77‐year‐old postmenopausal female patient who initially presented with lumbago and dizziness without typical pulmonary or gynecological symptoms, with an ECOG performance status of 1. Imaging studies raised suspicion of a primary uterine malignancy, but pathological biopsy, immunohistochemistry, and genomic testing ultimately confirmed advanced lung adenocarcinoma with multiorgan metastases (uterus, lung, liver, bone). Molecular analysis identified an EGFR exon 21 p.L858R mutation, and the patient received palliative local radiotherapy combined with osimertinib targeted therapy. During treatment, the patient developed mild radiation‐induced fatigue and slight myelosuppression, which were fully relieved after symptomatic supportive care, with no severe unexpected adverse events observed.
Conclusion
This case illustrates the atypical metastatic pattern of lung adenocarcinoma, underscores the pivotal role of pathological and immunohistochemical examinations in differentiating primary from metastatic tumors, and offers a reference for managing diagnostically challenging cases. Early and accurate diagnosis coupled with genomic‐guided personalized therapy is critical for enhancing quality of life and prognosis in patients with advanced lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Yancheng TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Yancheng, Jiangsu, People's Republic of China.
- Department of Laboratory Medicine, Yancheng TCM Hospital, Yancheng, Jiangsu, People's Republic of China.
- Jiangsu Vocational College of Medicine, Yancheng, Jiangsu, People's Republic of China.
- Department of Radiation Oncology, Yancheng No. 1 People's Hospital, Affiliated Hospital of Medical School, Nanjing University, Yancheng, Jiangsu, People's Republic of China.
- Department of Radiation Oncology, The First People's Hospital of Yancheng, Yancheng, Jiangsu, People's Republic of China.
ORCID-Profile: Pengpeng Sun, Yue Wang
Förderung
- Jiangsu Vocational College of Medicine University-Local Collaborative Innovation Research Project
Zitieren
APA
Sun, P., & Wang, Y. (2026). Metastatic Lung Adenocarcinoma to the Uterus Mimicking a Primary Uterine Malignancy: A Case Report. Cancer Reports. https://doi.org/10.1002/cnr2.70706
Vancouver
Sun P, Wang Y. Metastatic Lung Adenocarcinoma to the Uterus Mimicking a Primary Uterine Malignancy: A Case Report. Cancer Reports. 2026. doi:10.1002/cnr2.70706
BibTeX
@article{Sun2026,
author = {Sun, Pengpeng and Wang, Yue},
title = {Metastatic Lung Adenocarcinoma to the Uterus Mimicking a Primary Uterine Malignancy: A Case Report},
journal = {Cancer Reports},
year = {2026},
doi = {10.1002/cnr2.70706}
}
EUVIMED